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 Remarkable advances have been made in 
understanding the pathophysiology of 
thrombotic microangiopathy. As exempli-
fied by thrombotic thrombocytopenic 
purpura (TTP) and hemolytic uremic 
syndrome (HUS), thrombotic microan-
giopathy is characterized by thrombotic 
occlusion of the arterioles and capillaries. 
Th e thrombosis may involve the brain, 
kidney, and other vital organs and is asso-
ciated with serious morbidity and high 
mortality. With the exception of  Strepto-
coccus pneumoniae neuraminidase and 
the shiga toxins  of Escherichia coli or 
related microorganisms, the pathogenesis 
of thrombotic microangiopathy remained 
a mystery until recent years. 
It is now widely recognized that defec-
tive proteolysis of von Willebrand factor, 
due to genetic mutations of the 
 ADAMTS13 gene or autoantibodies of the 
ADAMTS13 metalloprotease, causes the 
microvascular thrombosis of TTP. 1 Among 
patients with atypical hemolytic uremic 
syndrome (aHUS), that is, those without 
evidence of infectious or other etiologies, 
three categories of abnormality have been 
detected in up to 50 % of the cases: inacti-
vating mutations involving the comple-
ment regulators, such as factor H (CFH), 
factor I (CFI), membrane cofactor protein 
(MCP, or CD46), C4b-binding protein, 
and thrombomodulin; autoantibodies of 
CFH; and gain-of-function mutations 
involving C3 convertase components, 
including C3 and complement factor B 
(CFB). 2,3 All of these abnormalities involve 
the complement system. It is assumed that 
uncontrolled activation of the complement 
cascade causes endothelial injury and 
microvascular thrombosis of aHUS. Nev-
ertheless, analysis of kindred suggests that 
the correlation between genetic mutations 
of the complement components and aHUS 
is anything but straightforward. 
 An obvious example of this complexity 
is the relatively low penetrance of the 
aHUS phenotype among patients with 
CFI mutations. Fremeaux-Bacchi  et al. 
fi rst described heterozygous mutations of 
 CFI in three patients with aHUS. 4 Yet nei-
ther of the two parents carrying the impli-
cated mutations ever developed aHUS. 
Such low penetrance has been repeatedly 
observed in subsequently reported pedi-
grees of  CFI mutations. 
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 Complement factor I ( CFI ) mutations are implicated in the pathogenesis 
of atypical hemolytic uremic syndrome (aHUS). Nevertheless, there is 
evidence that CFI deficiency is a weak effector of aHUS. Bienaime  et al. 
report that homozygous deletion of  CFHR-1 in the RCA gene cluster of 
chromosome 1q is a major risk factor for poor outcome for patients with 
 CFI mutations. The basic and clinical implications of the findings are 
further elaborated here. 
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 CFI is a plasma two-chain serine este-
rase that controls the amplifi cation loop 
of the alternative complement pathway. 
CFI cleaves the   -chains of C3b and C4b 
in the presence of CFH or MCP as a cofac-
tor. Inactivation of C3b and C4b prevents 
the formation of C3 / C5 convertases. 
When CFI is defi cient, relentless activa-
tion of the alternative pathway lowers the 
C3, factor B, CFH, and properdin levels. 
Consequently, deficiency of CFI is 
expected to predispose patients to bacte-
rial infections. 
 Hereditary defi ciency of CFI, previously 
known as C3b inactivator, was first 
described nearly four decades ago in a 
patient with a lifelong history of recurrent 
bacterial infection. 5 Since then, more than 
24 pedigrees with homozygous CFI defi -
ciency patients have been described. 
Recurrent bacterial infections have been 
the hallmark. Yet none of the patients with 
heterozygous or homozygous CFI defi -
ciency was noted to develop HUS. 
 To reconcile this apparent discordance 
between CFI defi ciency and aHUS, one 
may postulate that although it may be a 
risk factor, CFI defi ciency per se is insuf-
fi cient to cause HUS. What then are the 
other factors that are necessary to cause 
HUS in patients with CFI defi ciency? 
 Bienaime and colleagues 6 (this issue) 
identifi ed exonic mutations of  CFI in 23 
of a cohort of 202 aHUS patients. Inter-
estingly, 30 % of the patients with  CFI 
mutations carried at least one additional 
known genetic risk factor for aHUS, 
such as mutations in  CFH ,  MCP ,  C3 , or 
CFB. Additionally, 21 % of the patients 
w i t h   C F I  mut at i ons  c ar r i e d  a 
homozygous deletion of CFH-related 
protein 1 ( CFHR-1 ). In contrast, homo-
zygous deletion of  CFHR-1 is detected in 
2.9 % of the control population. 7 
 Th e conspicuous overrepresentation of 
homozygous  CFHR-1 deletion or other 
defects again strongly suggests that 
CFHR-1 protects patients with CFI defi -
ciency from developing aHUS. Th is inter-
pretation is further supported by the 
patients ’ outcomes. In the survival analysis, 
Bienaime  et al. report that more than 95 % 
of the patients with concurrent homozygous 
 CFHR-1 gene deletion died or developed 
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 Current evidence suggests that in many 
cases aHUS is the consequence of epistatic 
interactions of two or more genetic muta-
tions. Therefore, identification of one 
genetic mutation may not off er an ade-
quate guide of therapeutic decisions in 
individual cases. It has been proposed that 
patients with mutations involving circu-
lating proteins such as CFH and CFI 
respond well to plasma replacement 
therapy but have a very high risk of 
relapse after renal transplantation. In 
contrast, patients with mutations involv-
ing membrane-anchored proteins such 
as MCP do not respond well to plasma 
therapy but may be essentially cured with 
renal transplantation. Although this dis-
tinction has a rational basis, exceptions 
exist in published case reports. Th e dis-
tinction may be of little use for aHUS 
patients whose molecular defects are not 
completely defi ned. 
 As researchers continue the endeavor 
to attack the mysteries of aHUS, what 
can clinicians do to translate the recent 
advances into improved care for patients 
with aHUS? First, it is important to rec-
ognize that, although focal neurological 
deficits or mental changes are much 
more frequent in TTP and renal failure 
is much more prominent in aHUS, it is 
impossible to distinguish all cases of 
TTP, aHUS, and other types of throm-
botic microangiopathy solely on a clini-
cal basis. When a patient presents with 
thrombocytopenia and microangio-
pathic hemolysis, infectious etiologies, 
systemic autoimmune diseases such as 
lupus er ythematosus,  metastatic 
 neoplasms, HELLP syndrome (hemoly-
sis with elevated liver enzymes and low 
platelet count) during pregnancy, and 
potential medication culprits should be 
considered or excluded. For the diagno-
sis of TTP, measurements of ADAMTS13 
activity and inhibitors are becoming 
more readily available, although appro-
priate interpretation of the test results 
requires attention to certain potential 
laboratory pitfalls. Global complement 
assess such as CH50 and AH50 and indi-
vidual complement component meas-
urements may be used to assess the 
integrity of the complement system. 
Nevertheless, these tests do not invari-
ably detect abnormalities of the 
end-stage renal failure within 3 years. 6 In 
contrast, aft er 10 years such events had 
occurred in only 40 % of the patients with 
 ‘ exclusive ’  CFI mutations. Although the 
series of Bienaime  et al. 6 includes small 
numbers of cases, the diff erence in the out-
come between the groups with and without 
other mutations is striking. Further exam-
ination of the survival curves reveals that 
in the group with  ‘ exclusive ’  CFI mutations, 
the events of death or end-stage renal fail-
ure occurred within the fi rst 2 years of the 
disease onset, raising the possibility that 
those patients might have additional yet-
unidentifi ed abnormalities. 
 What may account for the diff erence in 
the outcome? Homozygous deletion of an 
84-kb genomic segment in the RCA (reg-
ulators of complement activation) gene 
cluster of chromosome 1q, which encom-
passes  CFHR-1 and  CFHR-3 , is a risk fac-
tor for aHUS, particularly in patients with 
autoantibodies of  CFH or  CFI mutations. 7 
Nevertheless, the deletion is quite com-
mon among normal subjects, indicating 
that deletion of  CFHR-1 (and  CFHR-3 ) is 
insuffi  cient to cause aHUS or renal failure. 
Could the absence of the CFHR-1 protein 
aggravate renal injury of excessive com-
plement activation caused by CFI 
 defi ciency? Th is scenario is certainly a 
possibility and is supported by a recent 
report that CFHR-1 blocks C5 convertase 
activity and the formation of the terminal 
complement complex ( Figure 1 ). 8 Never-
theless, one also needs to consider the 
possibility that the  CFHR-1 deletion allele 
may be linked to other as-yet unidentifi ed 
genetic variations that play a direct role in 
causing renal failure. 
 Another enigma is that diff erent disease 
phenotypes, including infections, mem-
branoproliferative glomerulonephritis type 
II (dense-deposit disease (DDD), OMIM 
 # 609814), and age-related macular degen-
eration (ARMD, OMIM  # 603075) as well 
as aHUS, have been independently associ-
ated with mutations of  CFH . 9 In contrast, 
DDD has not been associated with  CFI 
mutations. In fact, in mouse models of 
CFH defi ciency, the development of DDD 
requires the presence of CFI. 10 Further-
more, while the data of Bienaime  et al. 6 
suggest that homozygous deletion of 
 CFHR-1 is an important risk factor for 
poor outcome in patients with hetero-
zygous  CFI mutations, this same deletion 
genotype is reportedly protective against 
the development of ARMD. 11 It is appar-
ent that further mechanistic investigations 
will be needed to elucidate the pathophys-
iology of aHUS, ARMD, and DDD. 
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 Figure 1  |  Deficiency of complement factor H-related protein 1 aggravates the atypical 
hemolytic uremic syndrome in patients with complement factor I ( CFI ) mutations. This 
scheme depicts the roles of complement factor H (CFH), CFI, and CFH-related protein 1 (CFHR-1) in 
regulating the activation of the alternative complement pathway and the formation of the terminal 
complement complex C5b-9. Because activation of the alternative pathway is spontaneous, 
regulators are particularly critical for preventing its excessive activation. CFH, by binding to C3b, 
promotes the cleavage of the latter by CFI to iC3b. In addition, CFH also prevents the association of 
C3b with factor B, thereby preventing the formation of C3 convertase (C3bBb) and C5 convertase 
(C3bBbC3b). CFHR-1 binds to C5, inhibiting its activation by C5 convertase and the formation 
of the terminal complement complex (C5b-9). This scheme explains why, compared with CFH 
deficiency, CFI deficiency is a weak cause of atypical hemolytic uremic syndrome (aHUS). It also 
explains why CFHR-1 deficiency does not cause aHUS but markedly worsens aHUS in association 
with CFI deficiency. Other complement pathways, regulators, and receptors are not shown in this 
simplified scheme. 
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 complement system and do not provide 
a specifi c molecular diagnosis. Most of 
the genetic and molecular tests are not 
yet available for disease characterization 
in clinical laboratories. Referral to 
research laboratories is encouraged. 
However, regulatory concern, access, 
cost, and lengthy turnaround times ham-
per the role that research laboratories 
will play in clinical practice. 
With the defects of aHUS being charac-
terized in an increasing number of cases 
at the genetic and molecular levels, clini-
cians face a mounting challenge of deciding 
how to apply the vast albeit incomplete 
knowledge to the management of indi-
vidual patients.  In this regard, measures to 
block complement activation with inhibi-
tors such as eculizumab seem attractive for 
the treatment of aHUS. 12,13 Nevertheless, 
clinical experience with this therapeutic 
modality is quite limited for aHUS, and 
serious questions remain unanswered. It is 
hoped that with further elucidation of the 
molecular mechanisms, better measures 
will become available in the near future to 
tackle the serious business of aHUS. 
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 During hypoxic challenges, the reduced 
availability of oxygen triggers an increase 
in erythropoiesis of the organism, which 
results in an augmented oxygen-carrying 
capacity. In mammalians, this response to 
hypoxic stimuli is mediated by the eryth-
ropoiesis-stimulating hormone erythro-
poietin (EPO). With the exception of a 
few hepatic EPO-producing cells, the bulk 
of systemic EPO in adult mammals is gen-
erated in the renal cortex. 1,2 
 Increased production of EPO in 
response to hypoxic stimuli is virtually 
entirely due to enhanced transcriptional 
activity of the  EPO gene. Th e functional 
linkage between changes in tissue oxygen 
tension and altered EPO transcription 
is provided by the hypoxia-inducible 
transcription factors (HIFs). 
 HIF is a heterodimeric protein consist-
ing of an   - and a   -subunit. Th ree diff er-
ent   -subunits of HIF have been described 
(HIF-1  , HIF-2  , and HIF-3  ). Th e vari-
ous HIF  subunits are regulated by oxy-
gen tension at the protein level, whereas 
the   -subunit is constitutively expressed. 
In normoxia, HIF  is continuously syn-
thesized; however, steady-state levels in 
the cells are low, as HIF  is rapidly 
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 Functional evidence confirmed 
by histological localization: 
overlapping expression 
of erythropoietin and HIF-2  
in interstitial fibroblasts 
of the renal cortex 
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 Erythropoietin (EPO) is the central hormone in the regulation of 
erythropoiesis. Synthesis of EPO and its constitutive release into the 
circulation are controlled by the transcriptional activity of the  EPO gene. 
A key regulator of  EPO is the dimeric hypoxia-inducible transcription factor 
(HIF), which has three isoforms. Paliege and co-workers provide convincing 
morphological evidence that it is the HIF-2 isoform that essentially triggers 
 EPO in the kidney, which is the primary source of EPO in the body. 
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